Oral Recombinant Feline Interferon-Omega as an alternative immune modulation therapy in FIV positive cats: Clinical and laboratory evaluation

Research in Veterinary Science

Volumn 96, Issue 1, 2014, Pages 79-85

  Gil, S ^a   Leal, R O ^a   McGahie, D ^b   Sepulveda N ^c,d   Duarte, A ^a   Niza, M M R E ^a   Tavares, L ^a  

^a FACULDADE DE MEDICINA VETERINÁRIA   (Portugal)

^b Virbac SA   (France)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d Center of Statistics Applications of Lisbon University CEAUL   (Portugal)

Author keywords

Feline Immunodeficiency Virus (FIV); Immune modulation; Oral therapy; Recombinant Feline Interferon Omega (rFeIFN )

Indexed keywords

ACUTE PHASE PROTEIN; IMMUNOMODULATING AGENT; RECOMBINANT FELINE INTERON OMEGA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BIOCHEMISTRY; CAT; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; FELINE IMMUNODEFICIENCY VIRUS; FELINE IMMUNODEFICIENCY VIRUS INFECTION; HEMATOLOGY; IMMUNOMODULATION; LENTIVIRUS INFECTION; MICROBIOLOGICAL PARAMETERS; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ELECTROPHORESIS; SCORING SYSTEM; VIRAL EXCRETION;

FELIDAE; FELINE IMMUNODEFICIENCY VIRUS;

FELINE IMMUNODEFICIENCY VIRUS (FIV); IMMUNE-MODULATION; ORAL THERAPY; RECOMBINANT-FELINE INTERFERON OMEGA (RFEIFN-Ω);

ACUTE-PHASE PROTEINS; ADMINISTRATION, ORAL; ANIMALS; CATS; FECES; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNODEFICIENCY VIRUS, FELINE; IMMUNOLOGIC FACTORS; INTERFERON TYPE I; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; RNA, VIRAL; STATISTICS, NONPARAMETRIC;

EID: 84892515242     PISSN: 00345288     EISSN: 15322661     Source Type: Journal    
DOI: 10.1016/j.rvsc.2013.11.007     Document Type: Article

References (27)

1. Ackley C.D., Yamamoto J.K., Levy N., Pedersen N.C., Cooper M.D. Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. Journal of Virology 1990, 64:5652-5655.
2. Addie D. Feline coronavirus infections. Infectious Diseases of the Dog and Cat 2012, 92-108. Elsevier, Missouri. Elsevier ed. C. Green (Ed.).
3. Addie D., Belak S., Boucraut-Baralon C., Egberink H., Frymus T., Gruffydd-Jones T., Hartmann K., Hosie M.J., Lloret A., Lutz H., Marsilio F., Pennisi M.G., Radford A.D., Thiry E., Truyen U., Horzinek M.C. Feline infectious peritonitis. ABCD guidelines on prevention and management. Journal of Feline Medicine and Surgery 2009, 11:594-604.
4. Bracklein T., Theise S., Metzler A., Spiess B.M., Richter M. Activity of feline interferon-omega after ocular or oral administration in cats as indicated by Mx protein expression in conjunctival and white blood cells. American Journal of Veterinary Research 2006, 67:1025-1032.
5. Caney, S.H.C., Finerty, S., Tasker, S., Gruffydd-Jones, T.J., 2003. Treatment of asymptomatic chroniically FIV-infected cats with recombinant feline interferon omega. In: Proceedings of the Annual Conference of the American College of Veterinary Internal Medicine, Charlotte, USA.
6. Ceron J.J., Eckersall P.D., Martynez-Subiela S. Acute phase proteins in dogs and cats: current knowledge and future perspectives. Veterinary Clinical Pathology 2005, 34:85-99.
7. Coyne K.P., Gaskell R.M., Dawson S., Porter C.J., Radford A.D. Evolutionary mechanisms of persistence and diversification of a calicivirus within endemically infected natural host populations. Journal of Virology 2007, 81:1961-1971.
8. de Mari K., Maynard L., Sanquer A., Lebreux B., Eun H.M. Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus (FeLV)-infected and FeLV/feline immunodeficiency virus (FIV)-coinfected symptomatic cats. Journal of Veterinary Internal Medicine 2004, 18:477-482.
9. Domenech A., Miro G., Collado V.M., Ballesteros N., Sanjose L., Escolar E., Martin S., Gomez-Lucia E. Use of recombinant interferon omega in feline retrovirosis: from theory to practice. Veterinary Immunology and Immunopathology 2011, 143:301-306.
10. Flynn J.N., Cannon C.A., Lawrence C.E., Jarrett O. Polyclonal B-cell activation in cats infected with feline immunodeficiency virus. Immunology 1994, 81:626-630.
11. Gil S., Leal R.O., Duarte A., McGahie D., Sepulveda N., Siborro I., Cravo J., Cartaxeiro C., Tavares L.M. Relevance of feline interferon omega for clinical improvement and reduction of concurrent viral excretion in retrovirus infected cats from a rescue shelter. Research in Veterinary Science 2013, 94:753-763.
12. Gleich S., Hartmann K. Hematology and serum biochemistry of feline immunodeficiency virus-infected and feline leukemia virus-infected cats. Journal of Veterinary Internal Medicine 2009, 23:552-558.
13. Hartmann K. Clinical aspects of feline immunodeficiency and feline leukemia virus infection. Veterinary Immunology and Immunopathology 2011, 143:190-201.
14. Hennet P.R., Camy G.A., McGahie D.M., Albouy M.V. Comparative efficacy of a recombinant feline interferon omega in refractory cases of calicivirus-positive cats with caudal stomatitis: a randomised, multi-centre, controlled, double-blind study in 39 cats. Journal of Feline Medicine and Surgery 2011, 13:577-587.
15. Hosie M.J., Addie D., Belak S., Boucraut-Baralon C., Egberink H., Frymus T., Gruffydd-Jones T., Hartmann K., Lloret A., Lutz H., Marsilio F., Pennisi M.G., Radford A.D., Thiry E., Truyen U., Horzinek M.C. Feline immunodeficiency. ABCD guidelines on prevention and management. Journal of Feline Medicine and Surgery 2009, 11:575-584.
16. Ishida T., Shibanai A., Tanaka S., Uchida K., Mochizuki M. Use of recombinant feline interferon and glucocorticoid in the treatment of feline infectious peritonitis. Journal of Feline Medicine and Surgery 2004, 6:107-109.
17. Leal, R.O., Gil, S., Sepulveda, N., McGahie, D., Duarte, A., Niza, M.M.R.E., Tavares, L., 2012. Acute phase proteins: potential predictors of an immune-modulation in natural retroviral infected cats receiving recombinant interferon-omega therapy. In: Proceedings of the Annual Conference of the European College of Veterinary Internal Medicine - Companion Animals. Journal of Veterinary Internal Medicine (26) 1531, Maastricht, Netherlands.
18. Lutz H., Addie D., Belak S., Boucraut-Baralon C., Egberink H., Frymus T., Gruffydd-Jones T., Hartmann K., Hosie M.J., Lloret A., Marsilio F., Pennisi M.G., Radford A.D., Thiry E., Truyen U., Horzinek M.C. Feline leukaemia. ABCD guidelines on prevention and management. Journal of Feline Medicine and Surgery 2009, 11:565-574.
19. Lutz T.A., McGahie D., Albouy M. Impact of treatment with recombinant feline interferon omega on resolution of anorexia of unknown origin in cats 2011, European College of Veterinary Internal Medicine Congress, Sevilla, p. 1497.
20. Paltrinieri S. The feline acute phase reaction. Veterinary Journal 2008, 177:26-35.
21. Petersen H.H., Nielsen J.P., Heegaard P.M. Application of acute phase protein measurements in veterinary clinical chemistry. Veterinary Research 2004, 35:163-187.
22. Ritz S., Egberink H., Hartmann K. Effect of feline interferon-omega on the survival time and quality of life of cats with feline infectious peritonitis. Journal of Veterinary Internal Medicine 2007, 21:1193-1197.
23. Sarro Y.S., Tounkara A., Tangara E., Guindo O., White H.L., Chamot E., Kristensen S. Serum protein electrophoresis: any role in monitoring for antiretroviral therapy?. African Health Sciences 2010, 10:138-143.
24. Taylor S.S., Tappin S.W., Dodkin S.J., Papasouliotis K., Casamian-Sorrosal D., Tasker S. Serum protein electrophoresis in 155 cats. Journal of Feline Medicine and Surgery 2010, 12:643-653.
25. Tompkins W.A. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. Journal of Interferon & Cytokine Research 1999, 19:817-828.
26. Ueda Y., Sakurai T., Kasama K., Satoh Y., Atsumi K., Hanawa S., Uchino T., Yanai A. Pharmacokinetic properties of recombinant feline interferon and its stimulatory effect on 2',5'-oligoadenylate synthetase activity in the cat. The Journal of Veterinary Medical Science 1993, 55:1-6.
27. Yamamoto S., Shida T., Okimura T., Otabe K., Honda M., Ashida Y., Furukawa E., Sarikaputi M., Naiki M. Determination of C-reactive protein in serum and plasma from healthy dogs and dogs with pneumonia by ELISA and slide reversed passive latex agglutination test. The Veterinary Quarterly 1994, 16:74-77.